Jessica E. Bolden

6.2k total citations · 3 hit papers
17 papers, 4.9k citations indexed

About

Jessica E. Bolden is a scholar working on Molecular Biology, Immunology and Epidemiology. According to data from OpenAlex, Jessica E. Bolden has authored 17 papers receiving a total of 4.9k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 5 papers in Immunology and 3 papers in Epidemiology. Recurrent topics in Jessica E. Bolden's work include Protein Degradation and Inhibitors (5 papers), Histone Deacetylase Inhibitors Research (5 papers) and Ubiquitin and proteasome pathways (3 papers). Jessica E. Bolden is often cited by papers focused on Protein Degradation and Inhibitors (5 papers), Histone Deacetylase Inhibitors Research (5 papers) and Ubiquitin and proteasome pathways (3 papers). Jessica E. Bolden collaborates with scholars based in Australia, United States and Japan. Jessica E. Bolden's co-authors include Ricky W. Johnstone, Melissa J. Peart, Scott W. Lowe, Agustin Chicas, Zhen Zhao, Vishal Thapar, Darjus F. Tschaharganeh, Ailsa J. Frew, Brian M. Balgley and Xueping Fang and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Nucleic Acids Research.

In The Last Decade

Jessica E. Bolden

17 papers receiving 4.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Anticancer activities of histone deacetylase inhibitors

2006 2.4k citations Jessica E. Bolden, Melissa J. Peart et al. Nature Reviews Drug Discovery profile →
Control of the senescence-associated secretory phenotype by NF-κB promotes senescence and enhances chemosensitivity

2011 757 citations Yuchen Chien, Claudio Scuoppo et al. Genes & Development profile →
Non-Cell-Autonomous Tumor Suppression by p53

2013 615 citations Amaia Lujambio, Leila Akkari et al. Cell profile →

Peers

Countries citing papers authored by Jessica E. Bolden

Since Specialization

Citations

This map shows the geographic impact of Jessica E. Bolden's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jessica E. Bolden with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jessica E. Bolden more than expected).

Fields of papers citing papers by Jessica E. Bolden

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jessica E. Bolden. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jessica E. Bolden. The network helps show where Jessica E. Bolden may publish in the future.

Co-authorship network of co-authors of Jessica E. Bolden

This figure shows the co-authorship network connecting the top 25 collaborators of Jessica E. Bolden. A scholar is included among the top collaborators of Jessica E. Bolden based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jessica E. Bolden. Jessica E. Bolden is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	Identification of a Siglec-F+ granulocyte-macrophage progenitor 2018 ·Journal of Leukocyte Biology ·Jessica E. Bolden, Erin D. Lucas, Geyu Zhou, Jeremy A. O’Sullivan, Carolyn A. de Graaf, Mark McKenzie, Ladina Di Rago, Tracey M. Baldwin, Jake Shortt, Warren S. Alexander, Bruce S. Bochner, Matthew E. Ritchie, Douglas J. Hilton, Kirsten A. Fairfax	9
2	Transcriptional profiling of eosinophil subsets in interleukin-5 transgenic mice 2018 ·Journal of Leukocyte Biology ·Kirsten A. Fairfax, Jessica E. Bolden, (unknown), Erin D. Lucas, Tracey M. Baldwin, Kerry Ramsay, (unknown), Douglas J. Hilton, Carolyn A. de Graaf	10
3	Haemopedia RNA-seq: a database of gene expression during haematopoiesis in mice and humans 2018 ·Nucleic Acids Research ·Jarny Choi, Tracey M. Baldwin, (unknown), Jessica E. Bolden, Kirsten A. Fairfax, Erin D. Lucas, (unknown), Christine Biben, Clare Morgan, Kerry Ramsay, Ashley P. Ng, Maria Kauppi, Lynn M. Corcoran, Wei Shi, Nick Wilson, Michael J. Wilson, Warren S. Alexander, Douglas J. Hilton, Carolyn A. de Graaf	97
4	BRD4 Connects Enhancer Remodeling to Senescence Immune Surveillance 2016 ·Cancer Discovery ·Nilgun Tasdemir, Ana Banito, Jae‐Seok Roe, Direna Alonso‐Curbelo, Matthew Camiolo, Darjus F. Tschaharganeh, Chun‐Hao Huang, Ozlem Aksoy, Jessica E. Bolden, Chi-Chao Chen, Myles Fennell, Vishal Thapar, Agustin Chicas, Christopher R. Vakoc, Scott W. Lowe	278
5	Id2 and E Proteins Orchestrate the Initiation and Maintenance of MLL-Rearranged Acute Myeloid Leukemia 2016 ·Cancer Cell ·Margherita Ghisi, Lev M. Kats, Frédérick Masson, Jason Li, Tobias Kratina, Eva Vidacs, Omer Gilan, Maria Doyle, Andrea Newbold, Jessica E. Bolden, Kirsten A. Fairfax, Carolyn A. de Graaf, Matthew A. Firth, Johannes Zuber, Ross A. Dickins, Lynn M. Corcoran, Mark A. Dawson, Gabrielle T. Belz, Ricky W. Johnstone	26
6	Inducible In Vivo Silencing of Brd4 Identifies Potential Toxicities of Sustained BET Protein Inhibition 2014 ·Cell Reports ·Jessica E. Bolden, Nilgun Tasdemir, Lukas E. Dow, Johan H. van Es, John E. Wilkinson, Zhen Zhao, Hans Clevers, Scott W. Lowe	141
7	Abstract LB-40: Inducible in vivo silencing of Brd4 identifies potential toxicities of sustained BET protein inhibition 2014 ·Cancer Research ·Jessica E. Bolden, Nilgun Tasdemir, Lukas E. Dow, Johan H. van Es, John E. Wilkinson, Zhen Zhao, Hans Clevers, Scott W. Lowe	2
8	Molecular and Biologic Analysis of Histone Deacetylase Inhibitors with Diverse Specificities 2013 ·Molecular Cancer Therapeutics ·Andrea Newbold, Geoffrey M. Matthews, Michael Bots, Leonie A. Cluse, Christopher J. Clarke, (unknown), Carleen Cullinane, Jessica E. Bolden, Ailsa J. Christiansen, Ross A. Dickins, Claudia Miccolo, Susanna Chiocca, Astrid M. Kral, Nicole Ozerova, Thomas A. Miller, Joey L. Methot, Victoria M. Richon, J. Paul Secrist, Saverio Minucci, Ricky W. Johnstone	40
9	Non-Cell-Autonomous Tumor Suppression by p53 breakdown → 2013 ·Cell ·Amaia Lujambio, Leila Akkari, Janelle Simon, Danielle Grace, Darjus F. Tschaharganeh, Jessica E. Bolden, Zhen Zhao, Vishal Thapar, Johanna A. Joyce, Valery Krizhanovsky, Scott W. Lowe	615
10	The BTB-zinc Finger Transcription Factor Abrupt Acts as an Epithelial Oncogene in Drosophila melanogaster through Maintaining a Progenitor-like Cell State 2013 ·PLoS Genetics ·Nezaket Türkel, (unknown), Jessica E. Bolden, (unknown), Karen Doggett, Lee Willoughby, Enrique Blanco, Enrique Martı́n-Blanco, Montserrat Corominas, Jason Ellul, Toshiro Aigaki, Helena E. Richardson, Anthony M. Brumby	28
11	Control of the senescence-associated secretory phenotype by NF-κB promotes senescence and enhances chemosensitivity breakdown → 2011 ·Genes & Development ·Yuchen Chien, Claudio Scuoppo, Xiaowo Wang, Xueping Fang, Brian M. Balgley, Jessica E. Bolden, Prem K. Premsrirut, Weijun Luo, Agustin Chicas, Cheng S. Lee, Scott C. Kogan, Scott W. Lowe	757
12	Identification of Novel Ras-Cooperating Oncogenes in Drosophila melanogaster: A RhoGEF/Rho-Family/JNK Pathway Is a Central Driver of Tumorigenesis 2011 ·Genetics ·Anthony M. Brumby, (unknown), (unknown), Sherene Loi, Ryan Galea, (unknown), Jessica E. Bolden, Toshiro Aigaki, Patrick O. Humbert, Helena E. Richardson	65
13	Inducible activation of IFI 16 results in suppression of telomerase activity, growth suppression and induction of cellular senescence 2009 ·Journal of Cellular Biochemistry ·Christopher J. Clarke, Linda Hii, Jessica E. Bolden, Ricky W. Johnstone	17
14	Enhancing the apoptotic and therapeutic effects of HDAC inhibitors 2009 ·Cancer Letters ·Ailsa J. Frew, Ricky W. Johnstone, Jessica E. Bolden	195
15	The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy 2009 ·Blood ·Leigh Ellis, Michael Bots, Ralph K. Lindemann, Jessica E. Bolden, Andrea Newbold, Leonie A. Cluse, Clare L. Scott, Andreas Strasser, Peter Atadja, Scott W. Lowe, Ricky W. Johnstone	99
16	Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist 2008 ·Proceedings of the National Academy of Sciences ·Ailsa J. Frew, Ralph K. Lindemann, Ben P. Martin, Christopher J. Clarke, Janelle Sharkey, (unknown), Kellie-Marie Banks, Nicole M. Haynes, Pradnya Gangatirkar, Kym L. Stanley, Jessica E. Bolden, Kazuyoshi Takeda, Hideo Yagita∥, J. Paul Secrist, Mark J. Smyth, Ricky W. Johnstone	118
17	Anticancer activities of histone deacetylase inhibitors breakdown → 2006 ·Nature Reviews Drug Discovery ·Jessica E. Bolden, Melissa J. Peart, Ricky W. Johnstone	2401

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact